Zobrazeno 1 - 10
of 1 265
pro vyhledávání: '"anti-drug antibodies"'
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 208-215 (2024)
Introduction. Adalimumab, a fully humanized monoclonal antibody, is a tumor necrosis factor (TNFα) inactivator that is used against a number of autoimmune diseases such as rheumatoid arthritis and other most common inflammatory arthropathies (ankylo
Externí odkaz:
https://doaj.org/article/61c7f9e522ba49819af0b0a58b6b54e9
Autor:
A. N. Afanaseva, V. B. Saparova, I. E. Makarenko, T. A. Selmenskikh, D. V. Kurkin, A. L. Hohlov, R. V. Drai
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 247-255 (2024)
Introduction. Romiplostim is an analogue of the fusion protein peptide of thrombopoietin (TPO), which increases platelet count by binding and activating the human thrombopoietin receptor (TPO-R). It is used to treat thrombocytopenia associated with c
Externí odkaz:
https://doaj.org/article/b275653dfe8748d792b2e41f4c5157b3
Autor:
Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific
Externí odkaz:
https://doaj.org/article/9805ef0547804dc680ba4370dfa5869f
Autor:
Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTIn silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is ‘fully human’, T cell epitopes that are
Externí odkaz:
https://doaj.org/article/d3ac97f35912434aae9b77e2b10534c0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiaoliang Ding, Ling Xue, Mingjun Wang, Shengxiong Zhu, Kouzhu Zhu, Sheng Jiang, Jian Wu, Liyan Miao
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundAdalimumab induces the production of anti-drug antibodies (ADA) that may lead to reduced drug concentration and loss-of-response, posing significant clinical challenges. However, traditional immunoassays have limitations in terms of sensiti
Externí odkaz:
https://doaj.org/article/430ac58bb13b40348b442c36d8bfe89c
Autor:
Mark A. Kroenke, Marta Starcevic Manning, Christina L. Zuch de Zafra, Xinwen Zhang, Kevin D. Cook, Michael Archer, Martijn P. Lolkema, Jin Wang, Sarah Hoofring, Gurleen Saini, Famke Aeffner, Elizabeth Ahern, Elena Garralda Cabanas, Ramaswamy Govindan, Mun Hui, Shalini Gupta, Daniel T. Mytych
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/72f24fcbd43448008d13f236f8a3523a
Autor:
Renzo Mignani, Claudio Americo, Filippo Aucella, Yuri Battaglia, Vittoria Cianci, Annamaria Sapuppo, Chiara Lanzillo, Fabio Pennacchiotti, Luciano Tartaglia, Giacomo Marchi, Federico Pieruzzi
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Background Fabry disease is a rare progressive X-linked lysosomal storage disease caused by mutations in the GLA gene that encodes α-galactosidase A. Agalsidase beta is a recombinant enzyme replacement therapy authorized in Europe at a stan
Externí odkaz:
https://doaj.org/article/c127f7d8ac8b440fad79006e7c98871d
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 2, Pp 808-820 (2024)
Folic acid is a fully oxidized synthetic folate with high bioavailability and stability which has been extensively prescribed to prevent congenital disabilities. Here we revealed the immunosuppressive effect of folic acid by targeting splenic margina
Externí odkaz:
https://doaj.org/article/8cd3e9c02bba415792ddb10d5445ad44
Autor:
Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibod
Externí odkaz:
https://doaj.org/article/7b50e02d4e8d4d54b44bd8cfb4b2d620